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Lactate is a ubiquitous molecule in cancer. In this exploratory study, our aim was to
test the hypothesis that lactate could function as an oncometabolite by evaluating
whether lactate exposure modifies the expression of oncogenes, or genes encoding
transcription factors, cell division, and cell proliferation in MCF7 cells, a human breast
cancer cell line. Gene transcription was compared between MCF7 cells incubated in
(a) glucose/glutamine-free media (control), (b) glucose-containing media to stimulate
endogenous lactate production (replicating some of the original Warburg studies), and
(c) glucose-containing media supplemented with L-lactate (10 and 20mM). We found
that both endogenous, glucose-derived lactate and exogenous, lactate supplementation
significantly affected the transcription of key oncogenes (MYC, RAS, and PI3KCA),
transcription factors (HIF1A and E2F1), tumor suppressors (BRCA1, BRCA2) as well as
cell cycle and proliferation genes involved in breast cancer (AKT1, ATM, CCND1, CDK4,
CDKN1A, CDK2B) (0.001 < p < 0.05 for all genes). Our findings support the hypothesis
that lactate acts as an oncometabolite in MCF7 cells. Further research is necessary on
other cell lines and biopsy cultures to show generality of the findings and reveal the
mechanisms by which dysregulated lactate metabolism could act as an oncometabolite
in carcinogenesis.
Keywords: lactate, cancer, oncogenes, transcription factors, cell cycle genes
INTRODUCTION
A role of lactate in cancer metabolism was first described almost a century ago when OttoWarburg
and associates discovered that cancer cells were not only characterized by accelerated glucose
consumption, but also by a marked increase in lactate production (1). They exposed tumor cells to
amino acids, fatty acids, and glucose, expecting the highest rate of respiration in glucose-exposed
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cancer cells. Contrary to expectations, glucose brought
respiration to a standstill. “In trying to discover why this happened,
it was found that lactic acid appeared in the Ringer’s solution,
produced by glycolysis, and that this inhibited the respiration,”
asserted Warburg (2). Warburg also found that arterial glucose
uptake in tumor cells was about 47–70%, compared to 2–18%
in normal tissues, and that tumor cells converted 66% of
glucose uptake to lactate (3). Based on these observations,
Warburg concluded that increased glycolytic activity was integral
to carcinogenesis, a phenomenon subsequently termed the
“Warburg Effect” (4).
In the last decade there has been a “renaissance” of
cancer metabolism and the knowledge acquired has been
significant. It is now known that carcinogenesis involves complex
metabolic processes characterized by tumor heterogenicity,
involving different metabolic activities and regulations necessary
for tumor growth, survival and progression (5). Increasing
body of literature implicates the involvement of lactate for
carcinogenesis. Sonveaux et al. showed that lactate is a major fuel
for biomass and anabolic necessities of cancer cells (6, 7).
Given the unexplained causes and consequences of the
Warburg effect in cancer, recently, we articulated the
“lactagenesis hypothesis” (8). According to our hypothesis,
the predominant role of lactate in cancer is not only for fuel
or cancer biomass purposes but also for carcinogenic signaling
properties. Lactate is involved in the main biological processes
that are known to drive or sustain carcinogenesis, specifically:
angiogenesis, immune escape, cell migration, metastasis, and
self-sufficient metabolism (8).
While lactate has been the subject of intense investigation
since at least the nineteenth century, until recently it was believed
that lactate was solely a byproduct of oxygen-limited, anaerobic
metabolism. However, in the mid 1980’s George Brooks proposed
the “Lactate Shuttle Hypothesis” based on results of isotope tracer
studies in rodents and humans (9–13). His studies showed for
the first time that lactate production and exchange could also
occur under fully aerobic conditions debunking the belief that
lactate was a “waste” product of anaerobic glucose metabolism
(14). Specifically to cancer cells, it is estimated that in cancer cells,
lactate production accounts∼70% from aerobic glycolysis (15).
Furthermore, it is now recognized that lactate is a major
energy source (16–19), the major gluconeogenic precursor (19), a
signaling molecule and a “lactormone” (13) that also influences
gene expression (20–23). Exogenous L-lactate exposure, for
instance, has been reported to upregulate the transcriptional
activity of 673 genes in L6 cells (20). Hussien and Brooks later
showed that both lactate dehydrogenase A (LDHA) and LDHB
as well as monocarboxylate transporters (MCTs) were expressed
in breast cancer cells, including MCF7 (24).
Most recently, Zhang et al. (25) have shown that “lactylation”
of histone lysine residues serves as an epigenetic modification
that directly stimulates gene transcription from chromatin
in human and mouse cells. They also showed that lysine
lactylation (Kla) levels increased in a dose-dependent fashion
in response to exogenous L-lactate and that endogenous
production of lactate is a key determinant of histone Kla levels
(25). Furthermore, Verma’s group has recently and elegantly
demonstrated that tumor-mediated lactate can elicit epigenomic
reprograming of cancer-associated fibroblasts from pancreatic
ductal adenocarcinoma (26).
Moreover, there has been growing interest in blocking lactate
transport and exchange among and within cancer cells to
decrease tumor growth and carcinogenesis (6, 23, 27–29).
Renewed interest in understanding the causes and
consequences of the Warburg Effect has shown that lactate
can be produced from glutaminolysis. That observation is of
consequence because glutaminolysis is considered a hallmark of
cancer metabolism (30). It has been known since the 1970’s that
glutamine is a major energy source for mitochondria in HeLa
cells (31) as well as biomass precursor for the proliferation of
cancer cells (32). In pediatric glioblastoma cells (SF-188), MYC
overexpresses glutaminolysis to elicit a mitochondrial metabolic
reprograming favoring glutamine for energy purposes (33).
Beyond purposes of bioenergetics and biomass, glutaminolysis
can also be a major source of lactate in cancer (34). During
high rates of glutaminolysis (a typical characteristic in many
cancers) oxidative phosphorylation of glucose is decreased while
glutamine fermentation to lactate is increased (34). This concept
is important as it could explain why therapies targeting glycolysis
may not be very efficient if lactate is derived from glutamine.
Furthermore, recent research studies have focused on blocking
glutamine metabolism in cancer. In particular one recent study
in mouse cancer cells showed that a glutamine agonist JHU082
both shut down oxidative phosphorylation and glycolysis as well
as enhanced oxidative phosphorylation and immune response in
T-Cells (35).
In breast cancer, there is an average of about 33 somatic
mutations (36). Within the multiple somatic mutations in
different cancers, there are a few key driver genes that confer
a selective growth advantage to “drive” tumorigenesis (36, 37).
The driver genes involved in selective growth advantage are
referred to as “mut-driver” or “epi-driver” genes (36). Although
the epi-driver genes are not yet well-identified or understood,
125 mut-driver genes involved in multiple tumors have been
identified (36).
In the present study, we sought to determine whether
endogenously produced lactate or exogenously added
L-lactate (Sodium L-lactate) exposure could act as an
oncometabolite affecting the transcription of key driver
genes recognized to play a central role in breast cancer
(specifically in MCF7 cells).
MATERIALS AND METHODS
Overview
We tested our lactagenesis hypothesis by exposing MCF7
cells to glucose, which resulted in endogenously produced
lactate, or added, exogenous sodium L-lactate and observing
the transcription of key driver genes breast cancer, some of
which are involved in the majority of cancers (38–44). We took
this approach because of the orchestrated action of oncogenes,
tumor suppression genes, transcription factors and cell cycle
genes that activate an array of pathways leading to increased
cell proliferation and the metabolic reprograming of cancer cells
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from oxidative phosphorylation (OXPHOS) to glycolysis and
lactate production.
Cell Culture Experiments
For both study objectives MCF7 cells (ATCC) were maintained
in Dulbecco Modified Eagle Medium (DMEM) with 10% Fetal
Bovine Serum (FBS) and Penicillin 100 units/mL-Streptomycin
100 ug/mL (Invitrogen) [DMEM 10% FBS-Pen-Strep] and
cultured in a 5% CO2 atmosphere at 37◦C. Briefly, MCF7 cells
(1 × 106) were plated in cell culture dishes using DMEM 10%
FBS-PenStrep. Once the cells reached 80% confluence, the cells
were incubated in DMEM (high glucose; 4,500 mg/L) containing
0, 10, or 20mM sodium, L-lactate (Sigma) with 10% NuSerum
(BD Biosciences), and Pen-Strep. Controls were MCF7 cells
incubated in DMEM without glucose, glutamine, or lactate. Cells
were maintained for either 6 or 48 h before being harvested for
gene expression profiling. Cell pellets were stored in RLT buffer
(Qiagen) with beta mercaptoethanol added, and stored at−80◦C.
The concentration of lactate and glucose in the cell culture
media at the time of harvest was determined using the L-lactate
Assay Kit (AbCam) or Glucose Assay Kit (Cayman Chemical),
respectively, following manufacturer specifications.
Cell Line Authentication
MCF7 (ATCC R© HTB22TM) cells were authenticated by ATCC
using morphology, karyotyping, and PCR based approaches to
confirm identity of human cells and to rule out both intra- and
inter-species contamination. These included an assay to detect
species specific variants of the cytochrome C oxidase I gene
(COI), and short tandem repeat (STR) profiling. The cell line was
obtained inMarch of 2018 and the last test was done in September
of 2018.
RNA Isolation and Assessment of MCF7
Gene Expression
Total RNA was extracted using the AllPrep DNA/RNA Mini
Kit (Qiagen) and the quantity assessed using Nanodrop
spectrophotometry. RNA was reverse transcribed using a cDNA
conversion kit. The cDNA in combination with RT2 SYBR R©
Green qPCRMastermix was used on a Custom RT2 Profiler PCR
Array (Qiagen). RT2 Profiler PCR Arrays were used to compare
gene expression profiles between MCF7 cells cultured in glucose-
free media, glucose-supplemented media (leading to Warburg
Effect and lactate production) and glucose-supplemented media
with exogenous lactate added. Targeted genes typical of MCF-
7 cells included on the array were: oncogenes (MYC, NRAS,
and PIK3CA), transcription factors (HIF1A and E2F1), tumor
suppressor genes (BRCA1 and BRCA2) as well as cell cycle
genes, and proliferation genes (AKT1, ATM, CCND1, CDK4,
CDKN1A, CDK2b, and MIF) (Table 1). Genes were categorized
according to NIH Genetics Home Reference (www.ghr.nlm.nih.
gov). Each condition was run in triplicate, and from each of
the three biological replicates duplicate samples were run on the
expression array to ensure accuracy and reproducibility.
Statistical Analyses
Lactate and glucose concentrations were compared between
groups by analysis of variance (ANOVA) in GraphPad Prism (v.
5.01; GraphPad Software).
TABLE 1 | Fold changes in expression for cancer-related genes between glucose-starved MCF7 cells vs. MCF7 cells exposed to 0, 10, or 20mM lactate for 6 or 48 h.
Gene type+ Incubation duration 6 h Incubation duration 48 h
6h, 0 mM 6h, 10 mM 6h, 20 mM 48h, 0 mM 48h, 10 mM 48h, 20 mM
PROTO-ONCOGENES
NRAS – 3.56 – 2.31 2.58 1.92
PIK3CA – 4.31 – 2.04 2.20 2.03
MYC 1.88 7.75 6.28 3.33 2.80 2.81
CELL CYCLE/PROLIFERATION GENES
ATM – – – 8.14 4.04 4.22
CCND1 – 2.60 2.71 2.40 2.33 2.37
CDK4 2.51 6.36 5.64 3.97 3.59 3.02
CDK1A – 6.77 4.71 2.59 1.36 2.48
CDK2b 1.58 6.82 – 3.75 2.48 2.60
AKT1 1.98 3.35 1.46 2.15 2.72 1.75
MIF – 7.55 5.19 – – 2.09
TUMOR SUPPRESSOR GENES
BRCA1 1.70 3.42 3.71 3.42 4.27 2.43
BRCA2 – 6.14 5.55 4.88 4.94 3.31
TRANSCRIPTION FACTORS
HIF1A – 4.42 4.80 2.87 4.07 2.93
E2F1 1.58 3.37 3.28 2.30 2.56 1.68
Results are shown for genes showing a 1.5-fold or greater change in expression and a p-value ≤0.05.
+Genes classified according to NIH Genetics Home Reference (www.ghr.nlm.nih.gov).
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Cycle threshold (Ct) values, the number of PCR cycles
required for florescent signal to exceed background levels,
are inversely proportional to the amount of target nucleic
acid present in the sample. Ct values were exported and
then uploaded onto GeneGlobe, Qiagen’s data analysis web
portal (https://geneglobe.qiagen.com). Within the GeneGlobe
platform, 1Ct values were calculated by subtracting the Ct
value for the reference gene (GAPDH) from the Ct value for
target genes for each sample. For all experiments, controls
were MCF7 cells cultured in glucose/glutamine-free media
with 0mM lactate for 6 h to eliminate the impact of glucose-
derived endogenous lactate production (Warburg Effect) on
gene expression. Statistical tests were performed on raw 1Ct
values for each group. Fold change was then calculated
using 2−11CT formula. Gene expression differences between
experimental groups and controls are expressed as fold-
regulation. Criteria for reporting gene expression differences
include: fold-regulation of ≥2.0 with a p-value of ≤0.05.
Lactate and glucose concentrations were compared between
groups by analysis of variance (ANOVA) in GraphPad Prism
(v. 5.01; GraphPad Software).
RESULTS
Glucose-Derived Lactate Production
As expected, glucose incubation resulted in high
concentrations of lactate (28.8 ± 2.9 and 21 ± 6.8, mM
(p < 0.001) both 6 and 48 h, respectively post-incubation
in glucose (Figure 1). As no lactate was added in this
experiment in glutamine-free media, lactate accumulation
was considered to be glucose-derived as a result of the
Warburg Effect.
Glucose-Derived Endogenous Lactate
(Warburg Effect) Upregulates the
Transcriptional Activity of Oncogenes,
Transcription Factors, Tumor Suppressor
Factors as Well as Cell Cycle and
Proliferation Genes
Compared to controls, the expression of three key oncogenes,
MYC, RAS, and PIK3CA, was between 2- and 3.3-fold greater
in MCF7 cells cultured for 48 h in glucose-containing media
leading to lactate accumulation (p < 0.05) (Table 1, Figure 2).
Endogenous lactate production also affected the expression of
transcription factors known to be involved in MCF7 cancer
cells. Specifically, compared to controls, MCF7 cells cultured
in glucose-containing media for 48 h showed 2.9 and 2.3-fold
increases in mRNA expression of transcription factors HIF1A
and E2F1, respectively (p < 0.01) (Table 1, Figure 2). After 48 h
exposure, the transcriptional activity of tumor suppressor factors
BRCA1 and BCRA2 increased 3.4- to 4.9-fold, respectively (p
< 0.01) (Table 1, Figure 2). Finally, transcriptional activities of
cell cycle and proliferation genes (except for MIF) increased
2.1- to 8.1-fold (p < 0.05) (Table 1, Figure 2) after 48 h
exposure between.
FIGURE 1 | Glucose-derived lactate (Warburg Effect) in MCF-7 cells after 6
and 48 h of incubation in glucose (p < 0.001).
Exogenous Lactate Exposure Upregulates
the Transcriptional Activity of Oncogenes,
Transcription Factors, Tumor Suppressor
Factors as Well as Cell Cycle and
Proliferation Genes
10mM Lactate Exposures
Exposing MCF7 cells to 10mM lactate for 6 h increased the
expression of oncogenes MYC, NRAS, and PIK3CA between
3.6- and 7.8-fold (p < 0.05). After 48 h transcriptional activity
was slightly weaker for these oncogenes (2.6 and 2.8, p < 0.05)
(Table 1, Figure 3A). After 6 h, transcription factors, HIF1A and
E2F1, were overexpressed by 4.4- and 3.4-fold, respectively (p <
0.01) (Table 1, Figure 3A). Expression was similar after the 48 h
exposure for HIF1A 4.1-fold, p < 0.001), and slightly reduced
for E2F1 (2.6-fold, p < 0.001) (Table 1, Figure 3A). After 6 h,
transcriptional activity of tumor suppressor factors BRCA1 and
BRCA2 was increased between 3.4- and 6.1-fold, respectively (p
< 0.05). After 48 h exposure, transcriptional activities of BCRA1
and BCRA2 increased 4.3- to 4.9-fold, respectively (p < 0.001)
(Table 1, Figure 3A). Compared to controls, the transcriptional
activity of proliferation and cell cycle genes (except for ATM)
was significantly greater after 6 h exposure to 10mM lactate
with values ranging from 2.6- to 7.5-fold (all, p ≤ 0.05), while
a slightly weaker response was observed after the 48 h 10mM
lactate exposure with values (except MIF) ranging from 1.4- to
4-fold (all, p ≤ 0.05) (Table 1, Figure 3A).
20mM Lactate Exposures
In contrast to a 10mM lactate exposure, neither NRAS nor
PIK3CA gene expressions were increased compared to controls
in MCF7 cells, while MYC was increased by 6.3-fold (p <
0.05) when exposed to 20mM for 6 h (Table 1, Figure 3B).
However, 48 h exposure to 20mM lactate induced modest
increases in NRAS and PIK3CA gene expression (1.9- and 2.0-
fold, respectively, p< 0.01), and a slight decrease in expression of
MYC (2.8-fold, p< 0.01) (Table 1, Figure 3B).
Exposure to 20mM lactate also upregulated the expression
of several transcription factors after exposure of 6 or 48 h. At
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FIGURE 2 | Fold-regulation of Glucose-derived lactate (Warburg Effect) transcriptional activity for MCF7 cells cultured for 6 and 48 h in glucose media relative to
controls (MCF7 cells cultured in glucose/glutamine-free media) (p’s ≤ 0.05–0.01).
6 h, gene expression values for HIF1A and E2F1 were 4.8- and
3.3-fold, respectively greater than control (p < 0.05) while at
48 h exposure transcriptional activity for HIF1A and E2F1 was
slightly lower 2.9- to 1.7-fold, respectively (p < 0.05) (Table 1,
Figure 3B). Transcriptional activity of tumor suppressor factors
after 6 h exposures for BCRA1 and BCRA2 was increased by 3.7-
and 5.6-fold, respectively (p< 0.001) and was slightly lower after
the 48 exposure (2.4- to 3.3-fold, respectively, p< 0.001) (Table 1,
Figure 3B).
After 6 h exposures, the transcriptional activity of all cell cycle
genes except for ATM and CDK2b was overexpressed ranging
from 1.5- to 5.6-fold (all, p ≤ 0.05) (Table 1, Figure 3B). After
48 h, we observed increased transcriptional activity in all cell
cycle and proliferation genes studied ranging from 1.7- to 4.2-fold
(p < 0.05). Forty-eight hours exposures shown weaker response
than at 6 h, but still significant upregulation of cell cycle genes
(Table 1, Figure 3B).
DISCUSSION
Our findings demonstrate that in the MCF7 human breast
cancer cell line, lactate alters the transcriptional activity of
several key oncogenes as well as other driver genes involved in
metabolic reprograming as well as the regulation of cell cycle
and proliferation. In the aggregate, these observations are in line
with our “lactagenesis hypothesis” (8) positing augmented lactate
production for signaling carcinogenesis as one essential purpose
of the Warburg Effect.
After both 6 and 48 h exposures there was a high presence of
glucose-derived lactate in the cells incubated in glucose without
added lactate (or glutamine), which replicated the Warburg
studies (Figure 1). Previously, we have shown that lactate is
oxidized in mitochondrial preparations from non-transformed
tissues (14, 45, 46), and recently it has been confirmed that
lactate is also oxidized by mitochondria of cancer cells (6, 24)
purportedly for energetics (7, 24). Beyond lactate bioenergetics
and biomass properties, our study suggests that glucose-derived
lactate is sufficient to alter the transcriptional activity of key
oncogenes, transcription factor genes, tumor suppressor genes as
well as cell cycle, and proliferation genes, all of which are known
to be involved in the development of MCF7 breast cancer cells
(Table 1, Figure 2). The experiments, adding 10 and 20mM of
Lactate to MCF7 cells, augmented the transcriptional properties
of lactate (Table 1, Figures 3A,B) which supports the hypothesis
that lactate could be an oncogenic regulator, an oncometabolite.
Although lactate is the obligatory product of glycolysis under
fully aerobic conditions (13), and our findings indicate that the
addition of L-lactate to glucose (glutamine-free) media increases
the transcriptional activity of the candidate genes studied herein,
it is certainly possible that lactate and other metabolites involved
in glycolysis, the pentose phosphate pathway or the TCA cycle
could also influence the transcriptional activities of various genes
in tumorigenesis. For example, Damiani et al. have observed that
TCA intermediates that are not used for biomass purposes can
be disposed via lactate production (34). Hence, while lactate is a
metabolic intermediate, it has numerous downstream effects as
known to occur via cell redox changes (14), allosteric binding
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FIGURE 3 | Treatment with exogenous lactate (10 or 20mM) upregulates the expression of several key genes in MCF7 cells. The fold upregulation of expression with
6 and 48 h exposure to 10mM (A) or 20mM lactate (B) relative to controls (MCF7 cells cultured for 6 h in glucose/glutamine-free media) (p’s ≤ 0.05–0.001).
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(47), metabolic reprograming (26), and lactylation (25). The
downstream effects of lactate in cancer remain to be determined.
PIK3CA is considered to be the most mutated oncogene in
breast cancer (48, 49). Furthermore, PIK3CA mutations are key
drivers of breast cancer and its upregulation is associated with
poor prognosis (50). Noteworthy, PIK3CA mutations are more
frequent in estrogen receptor cancer cells, such as like MCF7
(51). In this study we demonstrate that lactate exposure to MCF7
cells is able to increase the transcriptional activity of PIK3CA
between 2.2- and 4.3-fold (p < 0.05–0.001) (Table 1, Figures 2,
3A,B). Furthermore, the PIK3/AKT/mTOR pathway is key and
important intracellular pathway with major role regulating cell
cycle, tumor growth, and proliferation (52, 53), one of the most
activated signaling pathways in breast cancer (52) as well as
required for survival of MCF7 (54).
In our study, we found that AKT1 transcriptional activity was
upregulated between 2- and 3.35-fold. The significant increase in
transcriptional activity elicited by lactate in both PIK3CA and
AKT1 implicates lactate as a signaling oncometabolite of the
key PIK3/AKT/mTOR pathway involved in the development of
many cancers.
Another major oncogene, MYC, is known to have multiple
roles in metabolic regulation including cellular adaptations
following endurance exercise training (55), but is frequently
overexpressed in breast cancer cells (56, 57), including MCF7
cells (58), and associated with poor prognosis (57). In our study,
we found thatMYC is highly expressed across all our experiments
between 2.8- and 7.7-fold (p< 0.01) (Table 1, Figures 2, 3A,B).
Hypoxia inducible factor 1 (HIF1α) as a major transcription
factor in cancer (39, 42). HIF1α increases the transcription of
genes regulating glucose transport and glycolytic enzymes (42),
eliciting a metabolic reprogramming, leading to the Warburg
Effect and lactate production. Furthermore, the overexpression
of HIF1A, the gene encoding HIF1α, plays an important role
in breast cancer tumor growth and metastasis as well as being
related to aggressiveness and poor prognosis (59–61). In all of our
lactate exposures experiments HIF1A transcriptional activity was
overexpressed (between 2.9- and 4.8-fold, p < 0.001) (Table 1,
Figures 2, 3A,B), a finding that is not novel, as others have
previously found similar results (22). Still, our present results
corroborate those of others showing an important effect of lactate
on transcriptional activities of this key transcription factor.
Our results showing an effect of lactate on expressions ofMYC
and HIF1A genes are consistent results of others showing an
upregulation of the glycolytic pathway in cancer (62, 63). Hence,
our results obtained on transcription of MYC and HIFA are
supportive our lactagenesis hypothesis.
BRCA1 and BRCA2 are tumor suppressor genes typically
mutated in breast cancer and highly connected with cancer
aggressiveness and survival (64–66). BRCA1 contributes to the
regulation of DNA repair, chromosomal remodeling, apoptosis,
cell-cycle control, and transcriptional activity (67). While the loss
or reduced expression of nuclear BRCA1 is prevalent in basal-
like breast cancers with negative estrogen, progesterone, and
epidermal growth factor receptors (triple negative), its cytosolic
expression is observed in estrogen-positive receptor breast
cancers (68). In estrogen-positive receptor breast cancer cells
(the characteristic of MCF7 cells), cytosolic BRCA1 expression
is inversely related to survival (68). Furthermore, transcriptional
activity of BRCA1 and BRCA2 genes has been observed in
multiple breast cancers (including MCF-7 cells) (69–71). In our
study, we found that lactate exposure is a potent regulator of
their transcriptional activity with increases in mRNA expression
between 3.3- and 6.1-fold (p< 0.001) (Table 1, Figures 2, 3A,B).
Increased cell cycle and proliferation is a characteristic of
cancer cells where all different phases in cell cycle are affected
in cancer mainly by cyclin-dependent kinases (CDKs) (72).
Among the significant results, we found that all CDKs were
overexpressed by lactate exposure in a range from 2- to 6.7-fold
(p < 0.01–0.05) (Table 1, Figures 2, 3A,B). While the trigger
of this genetic dysregulation hasn’t been elucidated, our data
show that most genes involved in the different phases of cell
cycle are overexpressed by glucose-derived lactate alone as well
as exogenous lactate; again, implicating lactate as a regulator of
CDKs, thus shedding new possible light in cancer cell division
and proliferation as well as therapeutics.
The traditional view of dysregulated downstream signaling
pathways in cancer is hierarchically mediated by somatic
mutations mainly due to dysregulation of oncogenes and tumor
suppressors (73, 74). Our results show that, at least inMCF7 cells,
lactate doesn’t obey a hierarchical order of signaling, and also
that in MCF7 cells, lactate signals multiple key steps essential in
carcinogenesis, including cell proliferation.
It has been estimated that each gene driver mutation confers
only a small selective growth advantage, about 0.4% increase
in the difference between cell birth and death (75). However,
this small difference over many years can result in significant
production and accumulation of tumor cells leading to cancer
(36). Likewise, we believe that a similar phenomenon can
hold true for the constant transcriptional activity elicited by
dysregulated lactate on the main key driver genes over the years.
Furthermore, Marticorena et al. (76) have recently shown
that genetic mutation alone could not be a necessary element
for cancer development as in their study, they found that both
non-cancerous and cancerous esophagus cells shared cancer-
associated genetic mutations.
Beyond the roles of oncogenes and tumor suppressor factors,
others have speculated that Epi-drivers, like epigenetic changes
affecting DNA and chromatin proteins could also be involved
in carcinogenesis (36). As mentioned above, a remarkable new
study by Zhang et al. has shown the regulation of gene expression
by histone “lactylation,” where both exogenous and endogenous
lactate levels stimulate gene transcription from chromatin in
human and mouse (25). From the extensive work of others, it
is known that many mechanisms are also involved in histone
acetylation in cancer. A classic example is the retinoblastoma
pathway. Once hypophosphorylated at the beginning of G1
phase, retinoblastoma protein (pRb) is hyperphosphorilated at
the end of G1 phase and the E2F1/pRB complex breaks off,
allowing transcriptional activity of E2F1 at the end of G1 phase.
E2F1 can then recruit histone acetylase for acetylation allowing
chromatin transcription of genes to facilitate cell cycle moving
passed the restriction (R) point into the G1/S transition and S-
phase of cell cycle. In our study we show that lactate increases
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E2F1 mRNA transcription between 1.6- and 4.1-fold (p < 0.05–
0.001). Again, results support our lactagenesis hypothesis.
In concert, here we show that at least in MCF7 cells, lactate
acts as an oncometabolite capable of regulating transcriptional
activities of key oncogenes, transcription factors, tumor
suppressors, and cell cycle genes involved in breast cancer.
An imperative question we pose now is what cell-specific
properties, and mechanisms allow lactate to induce candidate
cells toward a cancer phenotype. We have a plethora of
knowledge and expertise about muscle (77, 78) and whole-
body lactate metabolism during exercise (14) and as mentioned
vide supra, we have known for decades that lactate is a
major source of cellular energy, especially for mitochondria. In
normal physiology, there is a dynamic, order of magnitude,
range of muscle lactate production, and accumulation (14).
However, as a tissue, muscle is resistant to carcinogenesis.
In fact, rhabdomyosarcoma, historically thought to be a
rare form of muscle cancer, has been recently proven to
raise from endothelial progenitor cells following metabolic
reprogramming andmyogenic transdifferentiation, but not being
originated from myocytes in the tissue itself (79). As well,
from epidemiology, we know that regular exercise reduces the
incidences of some forms of cancers in addition to other chronic
diseases (80). Although lactate has been historically associated
to exercise, it is noteworthy to differentiate between effects
of transient increases in exercise-derived lactate and chronic
lactate elevation in cancer. During and after exercise, lactate
is ultimately cleared from muscle fibers with the clearance
rate depending on mitochondrial function and cardiometabolic
fitness level of the person. In contrast, in cancer, lactate is
not rapidly cleared, and is highly concentrated in the tumor
and its microenvironment; an effect of which could be to
promote carcinogenesis.
Study Limitations
We acknowledge that the present exploratory study has been
conducted on a cancer cell line (MCF7). Hence, for further testing
of the lactagenesis hypothesis will be important to reproduce
this study with other cancer cell lines as well as with tumor
biopsy cultures to show generality of the findings and reveal the
mechanisms by which dysregulated lactate metabolism could act
as an oncometabolite in carcinogenesis.
As well, we acknowledge that effects of treatment on gene
transcription are not perfect predictors of protein synthesis
and circulating protein levels. However, mRNA levels do show
a positive correlation with protein expression (81) with a
significant amount of protein (40%) being correlated to mRNA
levels (82). Likewise, protein expression alone is a perfect
predictor of the ultimate biological action, as the completion of
a biological action is due to a compendium of multiple epigenetic
effectors including the tumor microenvironment in the case of
cancer. In this exploratory study, our objective was to determine
the impact of lactate exposure on the expression of key genes
known to be involved in the pathogenesis of cancer in MCF7
cells. Future work will be expanded to include the assessment of
protein levels for differentially expressed genes.
In summary, our study supports the hypothesis that lactate
has the potential to serve as an oncometabolite, regulating
transcriptional activities of different key cancer-related genes
involved in metabolic reprograming as well as cell cycle and
proliferation (p’s < 0.05–0.001). Beyond present results with
MCF-7 cells additional studies on different cancer cell lines and
cultured tumor biopsy cells will be needed to further support
the lactagenesis hypothesis and to better understand the role of
lactate in carcinogenesis.
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